These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 16834735)

  • 1. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
    Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 8. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
    Dimichele D
    Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.
    Coppola A; Di Minno MN; Santagostino E
    Br J Haematol; 2010 Sep; 150(5):515-28. PubMed ID: 20573153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for adolescents with haemophilia and high titre inhibitors.
    Fox RA; Neufeld EJ; Bennett CM
    Haemophilia; 2006 May; 12(3):218-22. PubMed ID: 16643204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of current knowledge to the management of bleeding events during immune tolerance induction.
    Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
    Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of inhibitors.
    Astermark J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International workshop on immune tolerance induction: consensus recommendations.
    DiMichele DM; Hoots WK; Pipe SW; Rivard GE; Santagostino E
    Haemophilia; 2007 Jul; 13 Suppl 1():1-22. PubMed ID: 17593277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor development in haemophilia B: an orphan disease in need of attention.
    DiMichele D
    Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune tolerance in haemophilia: the long journey to the fork in the road.
    DiMichele DM
    Br J Haematol; 2012 Oct; 159(2):123-34. PubMed ID: 22924753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.